Exon-skipping therapies for Duchenne muscular dystrophy (eteplirsen, golodirsen, casimersen, viltolarsen)
Customize your policy alerts
Sign up for all Healthfirst policy alerts
Know when Healthfirst releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization, medical necessity, dosing, monitoring, billing, and coverage criteria for exon-skipping antisense oligonucleotide therapies for patients with Duchenne muscular dystrophy (DMD) within Healthfirst plans.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.